Stock Scorecard



Stock Summary for Anika Therapeutics Inc (ANIK) - $9.38 as of 8/29/2025 8:13:35 PM EST

Total Score

13 out of 30

Safety Score

34 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ANIK

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ANIK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ANIK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ANIK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ANIK (34 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ANIK

Wall Street Analysts See a 98.59% Upside in Anika ( ANIK ) : Can the Stock Really Move This High? 8/29/2025 1:55:00 PM
ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm - Anika Therapeutics ( NASDAQ:ANIK ) 8/26/2025 8:12:00 PM
Medtronic makes two key additions to its board. How activist Elliott can build shareholder value 8/23/2025 11:51:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK - Anika Therapeutics ( NASDAQ:ANIK ) 8/21/2025 6:17:00 PM
Bragar Eagel & Squire, P.C. Is Investigating Nutex, Anika, Fluor, and Inspire Medical and Encourages Investors to Contact the Firm - Anika Therapeutics ( NASDAQ:ANIK ) , Fluor ( NYSE:FLR ) 8/20/2025 8:57:00 PM
Anika ( ANIK ) Upgraded to Buy: Here's What You Should Know 8/20/2025 4:00:00 PM
ANIKA ( ANIK ) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm - Anika Therapeutics ( NASDAQ:ANIK ) 8/12/2025 11:34:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK - Anika Therapeutics ( NASDAQ:ANIK ) 8/9/2025 3:35:00 PM
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm - Anika Therapeutics ( NASDAQ:ANIK ) 8/4/2025 11:05:00 PM
Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. ( ANIK ) on Behalf of Investors - Anika Therapeutics ( NASDAQ:ANIK ) 8/1/2025 8:42:00 PM

Financial Details for ANIK

Company Overview

Ticker ANIK
Company Name Anika Therapeutics Inc
Country USA
Description Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 6/30/2025
Next Earnings Date 10/29/2025

Stock Price History

Last Day Price 9.38
Price 4 Years Ago 35.83
Last Day Price Updated 8/29/2025 8:13:35 PM EST
Last Day Volume 194,561
Average Daily Volume 140,302
52-Week High 26.00
52-Week Low 7.87
Last Price to 52 Week Low 19.19%

Valuation Measures

Trailing PE N/A
Industry PE 41.41
Sector PE 60.89
5-Year Average PE 0.60
Free Cash Flow Ratio 2.54
Industry Free Cash Flow Ratio 39.90
Sector Free Cash Flow Ratio 30.76
Current Ratio Most Recent Quarter 6.18
Total Cash Per Share 3.69
Book Value Per Share Most Recent Quarter 10.24
Price to Book Ratio 0.90
Industry Price to Book Ratio 5.00
Sector Price to Book Ratio 26.74
Price to Sales Ratio Twelve Trailing Months 1.16
Industry Price to Sales Ratio Twelve Trailing Months 4.43
Sector Price to Sales Ratio Twelve Trailing Months 13.32
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 14,418,100
Market Capitalization 135,241,778
Institutional Ownership 89.45%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 15.60%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -50.50%
Annual Earnings Growth 31.79%
Reported EPS 12 Trailing Months -0.90
Reported EPS Past Year -0.19
Reported EPS Prior Year -0.60
Net Income Twelve Trailing Months -60,626,000
Net Income Past Year -56,385,000
Net Income Prior Year -82,667,000
Quarterly Revenue Growth YOY -8.20%
5-Year Revenue Growth 0.91%
Operating Margin Twelve Trailing Months -14.80%

Balance Sheet

Total Cash Most Recent Quarter 53,167,000
Total Cash Past Year 55,629,000
Total Cash Prior Year 72,867,000
Net Cash Position Most Recent Quarter 53,167,000
Net Cash Position Past Year 55,629,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 153,989,000
Total Stockholder Equity Prior Year 212,265,000
Total Stockholder Equity Most Recent Quarter 147,672,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -535,000
Free Cash Flow Per Share Twelve Trailing Months -0.04
Free Cash Flow Past Year -2,331,000
Free Cash Flow Prior Year -7,215,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.26
MACD Signal -0.44
20-Day Bollinger Lower Band 7.59
20-Day Bollinger Middle Band 11.11
20-Day Bollinger Upper Band 14.63
Beta 0.64
RSI 48.66
50-Day SMA 15.67
150-Day SMA 22.11
200-Day SMA 23.57

System

Modified 8/29/2025 5:22:30 PM EST